Developmental models and hypothesis-driven early interventions in schizophrenia

doi:10.1017/CBO9780511735103.026

24 - Developmental models and hypothesis-driven early interventions in schizophrenia

Published online by Cambridge University Press: 04 August 2010

Matcheri S. Keshavan and

Barbara A. Cornblatt

Edited by

Matcheri S. Keshavan ,

James L. Kennedy and

Robin M. Murray

Show author details

Matcheri S. Keshavan: Affiliation:
University of Pittsburgh School of Medicine, Pittsburgh and Wayne State University School of Medicine, Detroit, USA
Barbara A. Cornblatt: Affiliation:
Recognition and Prevention Program, Lake Success, New York, USA
Matcheri S. Keshavan: Affiliation:
University of Pittsburgh
James L. Kennedy: Affiliation:
Clarke Institute of Psychiatry, Toronto
Robin M. Murray: Affiliation:
Institute of Psychiatry, London

Book contents

Get access

Summary

During recent years, three types of pathophysiological models have been proposed, those that posit altered pre- or perinatal brain development, those proposing peri-adolescent developmental abnormalities, and those that argue for neuronal degenerative processes after illness onset. This chapter reviews the lines of evidence from clinical observations and neurobiological research leading to the three seemingly conflicting models. It outlines an alternative model that potentially integrates all three. The chapter discusses the possible remediative and preventive treatment options suggested by the current pathophysiological models. It reviews the data that have emerged from the prevention programs generated by these models. The chapter is concluded by describing the way in which the unifying model newly proposed provides an integrated theoretical foundation for prevention and early intervention in schizophrenia. Evidence-based demonstration of cost effectiveness of such interventions is critically needed if this field of research is to sustain and solidify this paradigm shift.

Keywords

neurobiological research neurodegenerative model pathophysiological models schizophrenia peri-adolescent developmental abnormalities

Type: Chapter
Information: Neurodevelopment and Schizophrenia , pp. 455 - 472

DOI: https://doi.org/10.1017/CBO9780511735103.026 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akbarian, S., Bunney, W. E., Potkin, S. G.et al. (1993). Altered distribution of nicotamine-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50: 169–177CrossRef Google Scholar PubMed

Akbarian, S., Sucher, N., Bradley, D.et al. (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19–30CrossRef Google Scholar PubMed

Andreasen, N., Rezai, K., Alliger, R.et al. (1992). Hypofrontality in neuroleptic-naive patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49: 943–958CrossRef Google Scholar PubMed

Arnt, J., Skarsfeldt, T. (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63–101CrossRef Google Scholar

Bechdolf, , A., Wagner, M. (2003). Cognitive behavioral therapy in the prepsychotic phase: an exploratory study. Schizophr Res 60(Suppl.): 319CrossRef Google Scholar

Behar, T. N., Scott, C. A., Greene, C. L.et al. (1999). Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 19: 4449–4461CrossRef Google Scholar PubMed

Berger, G. E., Profitt, T. M., McConchie, M. A.et al. (2004). Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis, Schizophr Res 67: 7

Cannon, T. D., Huttunen, M. O., Dahlstrom, M.et al. (2002). Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry 159: 1230–1232CrossRef Google Scholar PubMed

Christodolou, G. N. (1991). Prevention of psychopathology with early interventions. Psychother Psychosom 55: 201–207CrossRef Google Scholar

Chugani, H. T., Phelps, M. E., Mazziotta, J. C., (1987). Positron-emission tomography study of human brain functional development. Ann Neurol 22: 487–497CrossRef Google Scholar PubMed

Cornblatt, B. A., Malhotra, A. K. (2001). Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet 105: 11–153.0.CO;2-G>CrossRef Google Scholar PubMed

Cornblatt, B., Lencz, T., Correll, C., Author, A., Smith, C. (2002). Treating the prodrome naturalistic findings from the RAP Program. Acta Psychiatr Scand 106(S413): 44Google Scholar

Cornblatt, B. A., Lencz, T., Smith, C. W.et al. (2003). The schizophrenia program revisited: a neurodevelopmental perspective. Schizophr Bull 29: 633–651CrossRef Google Scholar PubMed

Coyle, J. T. (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3: 241–253CrossRef Google Scholar

Cuijpers, P. (2003). Examining the effects of prevention programs on the incidence of new cases of mental disorders: the lack of statistical power. Am J Psychiatry 160: 1385–1391CrossRef Google Scholar PubMed

DeLisi, L. E. (1995). A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry 38: 349–360CrossRef

DeLisi, L. E.DeLisi, L. E. (1997). Is schizophrenia a lifetime disorder of brain plasticity, growth, and aging?Schizophr Res 23: 119–129CrossRef Google Scholar PubMed

Deutsch, S. I., Rosse, R. B., Schwartz, B. L., Mastropaolo, J. (2001). A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24: 43–49CrossRef Google Scholar PubMed

Done, D. J., Crow, T. J., Johnstone, E. C., Sacker, A. (1994). Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. Br Med J 309: 699–703CrossRef Google Scholar PubMed

Eastwood, S. L., Harrison, P. J. (1995). Decreased synaptophysin in the medical temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience 69: 339–343CrossRef Google Scholar

Eaton, W. W., Thara, R., Federman, B., Melton, B., Liang, K. Y. (1995). Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 52: 127–134CrossRef

Elvevag, B., Goldberg, T. E. (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14: 1–21CrossRef Google Scholar PubMed

Erlenmeyer-Kimling, L., Cornblatt, B. A. (1992). A summary of attentional findings in the New York High-risk Project. J Psychiatr Res 26: 405–426CrossRef Google Scholar PubMed

Erlenmeyer-Kimling, L., Squires-Wheeler, E., Hilldoff-Adamo, U. H., et al. (1995). The New York High-risk Project. Psychoses and cluster A personality disorders in offspring of schizophrenic parents at 23 years of follow-up. Arch Gen Psychiatry 52: 857–865CrossRef Google Scholar

Feinberg, I. (1982–83). Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?J Psychiatr Res 17: 319–334CrossRef Google Scholar

Feinberg, I.Feinberg, I. (1990). Cortical pruning and the development of schizophrenia. Schizophr Bull 16: 567–570CrossRef Google Scholar PubMed

Fenton, W. S., McGlashan, T. H. (1994). Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 151: 351–356Google Scholar

Fish, B. (1987). Infant predictors of the longitudinal course of schizophrenic development. Schizophr Bull 13: 395–409CrossRef Google Scholar PubMed

Garey, L. J., Ong, W. Y., Patel, T. S., et al. (1998). Reduced dendritic spines density on cerebral cortical pyramidal cells in schizophrenia. J Neurol Neurosurg Psychiatry 65: 446–453CrossRef Google Scholar

Glantz, L. A., Lewis, D. A. (1997). Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: Regional and diagnostic specificity. Arch Gen Psychiatry 54: 943–952CrossRef Google Scholar PubMed

Goff, D. C., Coyle, J. T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367–1377CrossRef Google Scholar PubMed

Grace, A. (1993). Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neur Transm (Gen Sect) 91: 111–134CrossRef Google Scholar

Haas, G., Sweeney, J. (1992). Premorbid and onset features of first-episode schizophrenia. Schizophr Bull 18: 373–386CrossRef Google Scholar PubMed

Hafner, H., Maurer, K., Loffler, W., Riecher-Rossler, A. (1993). The influence of age and sex on the early course of schizophrenia. Br J Psychiatry 162: 80–86CrossRef Google Scholar PubMed

Heresco-Levy, U., Javitt, D. (1998). The role of N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8: 141–152CrossRef Google Scholar PubMed

Hoffman, R., McGlashan, T. (1997). Synaptic elimination, neurodevelopment, and the mechanism of hallucinated “voices” in schizophrenia. Am J Psychiatry 154: 1683–1689CrossRef Google Scholar

Jaskiw, G. E., Juliano, D. M., Goldberg, ,T. E., et al. (1994). Cerebral ventricular enlargement in schizophreniform disorder does not progress. A seven year follow-up study. Schizophr Res 14: 23–28CrossRef Google Scholar

Javitt, D., Zukin, S. (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301–1308Google Scholar PubMed

Jernigan, T. L., Tallal, P. (1990). Late childhood changes in brain morphology observable with MRI. Dev Med Child Neurol 32: 379–385CrossRef Google Scholar PubMed

Johnstone, E. C., Russell, K. D., Harrison, L. K., Lawrie, S. M. J. (2003). The Edinburgh High Risk Study: current status and future prospects. World Psychiatry 2: 45–49Google Scholar PubMed

Jones, P., Cannon, M. (1998). The new epidemiology of schizophrenia. Psychiatr Clin North Am 21: 1–25CrossRef Google Scholar PubMed

Keshavan, M., Anderson, S., Pettegrew, J. (1994). Is schizophrenia due to excesive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res 28: 239–265CrossRef Google Scholar

Keshavan, M. S.Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. (1999). J Psychiatr Res 33: 513–521CrossRef Google Scholar PubMed

Keshavan, M. S., Hogarty, G. E. (1999). Brain maturational processes and delayed onset in schizophrenia. Dev Psychopathol 11: 525–543CrossRef Google Scholar

Keshavan, M. S., Reynolds, C. F., Miewald, M. J.et al. (1998a). Delta sleep deficit in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry 55: 443–448CrossRef Google Scholar

Keshavan, M., Haas, G., Kahn, C.et al. (1998b). Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?J Psychiatr Res 32: 60–65CrossRef Google Scholar

Keshavan, M. S., Stanley, J. A., Montrose, D. M., Minshew, N. J., Pettegrew, J. W. (2003). Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo (31)P MRS study. Mol Psychiatry 8: 316–323CrossRef Google Scholar

Kim, J., Kornhuber, H., Schmid-Burgk, W., Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382CrossRef Google Scholar

Kovelman, J., Scheibel, A. (1984). A neurohistological correlate of schizophrenia. Biol Psychiatry 19: 1601–1621Google Scholar PubMed

Kraepelin, E. (1919). Dementia Praecox and Paraphrenia. Edinburgh: E. and S. Livingstone

Lieberman, J. (1993). Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 54(Suppl.): 13–17Google Scholar PubMed

Lieberman, J., Koreen, A., Chakos, M.et al. (1996). Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 9: 5–9Google Scholar

Lieberman, J., Sheitman, B., Kinon, B. (1997). Neurochemical sensitization in the pathophysiology of schiozphrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205–229CrossRef Google Scholar PubMed

Lieberman, J., Chakos, M., Wu, H.et al. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 49: 487–499CrossRef Google Scholar PubMed

Loebel, A. D., Liberman, J. A., Alvir, J. M. J. (1992). Duration of psychosis and outcome in first-episode schiozphrenia. Am J Psychiatry 149: 1183–1188Google Scholar

Mathalon, D. H., Ford, J. M., Rosenbloom, M., Pfefferbaum, A. (2000). P300 reduction and prolongation with illness duration in schizophrenia. Biol Psychiatry 47: 413–427CrossRef Google Scholar

McGlashan, T., Fenton, W. (1993). Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 19: 71–84CrossRef Google Scholar PubMed

McGlashan, T. H., Hoffman, R. E. (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57: 637–648CrossRef Google Scholar PubMed

McGlashan, T. H., Zipursky, R. B., Perkins, D.et al. (2003a). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 61: 7–18CrossRef Google Scholar

McGlashan, T. H., Zipursky, R. B., Perkins, D.et al.McGlashan, T. H., Zipursky, R. B., Perkins, D.et al. (2003b). Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophr Res 60(Suppl.): 295CrossRef Google Scholar

McGorry, P. D., Yung, A. R., Phillips, L. J.et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59: 921–928CrossRef Google Scholar

McGrath, J. (2000). Universal interventions for the primary prevention of schizophrenia. Aust N Z J Psychiatry 34(Suppl.): S58–S64CrossRef Google Scholar PubMed

Meltzer, H. (1994). An overview of the mechanism of action of clozapine. J Clin Psychiatry 55: 47–52Google Scholar PubMed

Mednick, S. A., Machon, R. A., Huttunen, M. O. (1988). Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45: 171–176CrossRef Google Scholar

Moghaddam, B. (2002). Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 51: 775–787CrossRef Google Scholar PubMed

Morrison, A. P., Bentall, R. P., French, P.et al. (2002). Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry Suppl 43: S78–S84CrossRef Google Scholar PubMed

Mrazek, P. J., Haggerty R. J. (1994). Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academy Press

Murray, R. M., Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental disorder? [Editorial] Br Med J (Clin Res Ed) 295: 681–682CrossRef Google Scholar PubMed

Olney, J., Farber, N. (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998–1007CrossRef

Pettegrew, J. W., Keshavan, M. S., Panchalingam, K., et al. (1991). Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry 48: 563–568CrossRef

Pettegrew, J. W., McClure, R., Keshavan, M., et al. (1997). 31P magnetic resonance spectroscopy studies of developing brain. In Neurodevelopment and Adult Psychopathology, ed. M. Keshavan, R. Murray. New York: Cambridge University Press, pp. 71–92

Ruhrmann, S., Wagner, M., Wieneke, A., et al. (2002). Intervention in the initial phase of psychosis. Acta Psychiatr Scand 106(S413): 19Google Scholar

Scott, L., Kruse, M. S., Forssberg, H.et al. (2002). Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc Natl Acad Sci USA 99: 1661–1664CrossRef Google Scholar PubMed

Selemon, J., Rajkowska, G., Goldman-Rakic, P. (1995). Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry, 52: 805–818CrossRef Google Scholar PubMed

Susser, E. S., Lin, S. P. (1992). Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944–1945. Arch Gen Psychiatry 49: 983–988CrossRef Google Scholar PubMed

Tamminga, C. A. (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21–36CrossRef Google Scholar PubMed

Thompson, P. M., Vidal, C., Giedd, J. N.et al. (2001). Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 98: 11650–11655CrossRef Google Scholar PubMed

Tsai, G., Passani, L., Slusher, B.et al. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenia brains. Arch Gen Psychiatry 52: 829–836CrossRef Google Scholar

Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660–669CrossRef Google Scholar PubMed

Weinberger, D. R.Weinberger, D. R. (1995). From neuropathology to neurodevelopment. Lancet 346: 552–557CrossRef Google Scholar PubMed

Weinberger, D. R., McClure, R. K. (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?Arch Gen Psychiatry 59: 553–558CrossRef Google Scholar PubMed

Woods, S. W., D'Souza, D. C., Wexler, B. E., Hoffman, R. E., McGlashan, T. H. (2002). Novel early interventions for prodromal states. Acta Psychiatr Scand 106(S413): 12Google Scholar

Woods, S. W., Breier, A., Zipursky, R. B.et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 54: 453–464CrossRef Google Scholar PubMed

Wyatt, R. (1991). Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325–351CrossRef Google Scholar PubMed

Zipursky, R. O. (1992). Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 49: 195–205CrossRef Google Scholar

Book contents

24 - Developmental models and hypothesis-driven early interventions in schizophrenia

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive